Clinical trial
Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of…
NCT00242918 · Benaroya Research Institute, Other · Completed
Key facts
| NCT number | NCT00242918 |
|---|---|
| Title | Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer |
| Official title | Phase II Trial of Neoadjuvant Docetaxel and ZD 1839 (Iressa) Followed by Radical Prostatectomy in Patients With High Risk, Locally Advanced Prostate Cancer |
| Lead sponsor | Benaroya Research Institute, Other |
| Collaborators | AstraZeneca Industry Sanofi |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, ZD1839 |
| Enrollment | 29 |
| Start date | May 1, 2003 |
| Completion | Nov 1, 2007 |
| First posted | Oct 21, 2005 |
| Last update posted | Feb 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: